Mangiferin was verified to inhibit activation of the noncanonical NF-κB pathway by TWEAK treatment in glioma cells, as seen with a reduction in p100-p52 processing and RelB (Figure 3C). This evidence concerns the gene NFKB1 and central nervous system cancer.